Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea Apnimed Completes Enrollment in Ph3 LunAIRo Study of AD109, Potential 1st Nighttime Oral Tx for Obstructive Sleep Apnea; Presents Study Design at ATS2024

Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference

Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea Apnimed Announces New Leadership Appointments as It Builds Commercial & HR Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for OSA